Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Osilodrostat and Cabergoline Versus Osilodrostat Alone in Cushing's Disease in Iraq: Assessment of Efficacy and Safety

NCT07603466 is registered in ClinicalTrials.gov with University of Basrah as lead sponsor.

NCT NCT07603466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07603466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Osilodrostat and Cabergoline Versus Osilodrostat Alone in Cushing's Disease in Iraq: Assessment of Efficacy and Safety
Lead sponsor
University of Basrah
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
May 11, 2026
Completion date
August 31, 2028
Enrollment
50 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cushing disease due to increased acth secretion